Chronic GvHD Clinical Trial Landscape

The chronic GVHD trial landscape in 2026

Chronic graft-versus-host disease (cGVHD) is the leading cause of late non-relapse mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It affects an estimated 30–50% of allo-HSCT recipients who survive beyond day 100, manifesting as an immune dysregulation syndrome in which donor T cells and macrophages attack recipient tissues. The clinical spectrum ranges from mild skin and mucosal involvement to life-threatening pulmonary, hepatic, and gastrointestinal disease.

For most of the 2000s and 2010s, systemic corticosteroids remained the standard first-line treatment despite poor long-term outcomes and high steroid toxicity burden. That is now changing. Between 2017 and 2024, four new drugs received FDA approval for steroid-refractory cGVHD: ibrutinib (2017), ruxolitinib (2021), belumosudil (2021), and axatilimab (2024). The field has shifted from steroid monotherapy to a multi-agent landscape with mechanistically distinct options across lines of therapy.

In 2026, 11 trials are actively recruiting cGVHD patients on ClinicalTrials.gov. The dominant story is Incyte Corporation's push to move axatilimab from its third-line approved indication into earlier lines — including a Phase 3 trial of axatilimab plus corticosteroids as initial therapy for newly diagnosed cGVHD.

Current cGVHD trial activity (as of early 2026)

Based on ClinicalTrials.gov data updated daily by DataLookout:

The cGVHD competitive landscape in 2026

Axatilimab (Incyte) — moving up the line

Axatilimab-csfr (NIKTIMVO) received FDA approval in August 2024 for adults with recurrent or refractory cGVHD after at least two prior lines of systemic therapy — making it the newest approved drug in this indication and the first anti-CSF1R antibody approved for any indication. The drug works by blocking the colony-stimulating factor 1 receptor (CSF1R) on macrophages, depleting the tissue-resident macrophage populations that drive fibrotic cGVHD pathology. This mechanism is distinct from all prior approved cGVHD drugs, which targeted T cell signaling (ibrutinib), JAK-STAT signaling (ruxolitinib), or ROCK2 (belumosudil).

With 3L+ approval secured, Incyte is now running three additional axatilimab trials to expand the drug's label and market position. The most strategically important is NCT06585774 — a Phase 3 study of axatilimab combined with corticosteroids as initial treatment for newly diagnosed cGVHD. If successful, this trial would move axatilimab from a rescue therapy to a first-line standard of care, dramatically expanding the addressable patient population. First-line cGVHD is a much larger market than 3L+: nearly every allo-HSCT patient who develops cGVHD receives initial therapy.

The Phase 2 combination trial with ruxolitinib (NCT06388564) tests a mechanistically rational pairing — ruxolitinib addresses T-cell-driven inflammation via JAK inhibition while axatilimab targets the macrophage-driven fibrotic component. This combination could address both the inflammatory and fibrotic dimensions of cGVHD simultaneously, two distinct biological processes that individual agents may not fully control alone. Incyte also initiated a pediatric axatilimab study (AGAVE-256, NCT07124078) to extend the approval to children with cGVHD after 2+ prior lines.

Belumosudil (Sanofi/Kadmon) — prevention strategy

Belumosudil (REZUROCK), the ROCK2 inhibitor approved in 2021 for 3L+ cGVHD, is being studied at Memorial Sloan Kettering in a Phase 2 prevention trial (NCT07006506) — evaluating whether earlier belumosudil administration can prevent cGVHD from developing in high-risk allo-HSCT patients. Prevention is a high-value strategy: if GVHD can be blocked before it becomes established, the treatment burden and organ damage accumulation that characterize moderate-to-severe cGVHD would be avoided entirely. Prevention labeling would also open the entire allo-HSCT population as a drug-eligible cohort, not just those who develop cGVHD.

Ruxolitinib (Incyte/Novartis) — aGVHD expansion

Ruxolitinib (Jakafi) received FDA approval for acute GVHD (steroid-refractory, adults and children ≥12) in 2019, before its 2021 cGVHD approval. The MAGIC consortium's Phase 2 trial (NCT06936566) is studying ruxolitinib for aGVHD — testing a standardized dosing and management protocol across multiple transplant centers. The MAGIC trial reflects the ongoing academic effort to optimize ruxolitinib use and identify which aGVHD patients respond best, informing personalized treatment decisions in a disease where individual responses to JAK inhibition are heterogeneous.

AC-003 (Accro Bioscience) — early-phase entry

Accro Bioscience, a Chinese biotech, is running a Phase 1b study of AC-003 in aGVHD patients (NCT07070674). AC-003 represents one of several early-stage programs entering the GVHD space from Asian biotechs, where high allo-HSCT transplant volumes at major centers provide a large patient pool for early clinical studies. As with other Phase 1 assets, AC-003's mechanism and differentiation from existing approved drugs will emerge with Phase 1 data publication.

Post-transplantation cyclophosphamide optimization (Shanghai Jiao Tong)

The second Phase 3 trial (NCT06705062) is not a drug trial in the traditional sense — it compares reduced-dose versus standard-dose post-transplantation cyclophosphamide (PTCy) as GVHD prophylaxis following allo-HSCT. PTCy has become a standard GVHD prevention strategy at many transplant centers globally, replacing calcineurin inhibitors in some protocols. Optimizing PTCy dosing to reduce toxicity while maintaining GVHD prevention efficacy is an important question for the large population of patients undergoing allo-HSCT with PTCy-based prophylaxis. This trial represents infrastructure-level optimization of transplant practice rather than a novel therapeutic mechanism.

What DataLookout monitors for chronic GVHD

Configure your profile with condition and drug keywords for targeted cGVHD monitoring:

• Condition terms: "chronic graft-versus-host disease", "cGVHD", "chronic GVHD", "graft versus host disease"
• By drug/mechanism: "axatilimab", "belumosudil", "ruxolitinib GVHD", "CSF1R cGVHD", "ROCK2 GVHD", "JAK inhibitor GVHD"
• By line of therapy: "first-line cGVHD", "steroid-refractory GVHD", "refractory cGVHD", "newly diagnosed GVHD"
• By sponsor: "Incyte GVHD", "Sanofi GVHD", "Kadmon GVHD" for company-specific intelligence
• By form: "acute GVHD", "aGVHD" for acute-form monitoring alongside chronic programs

Who uses chronic GVHD trial monitoring

Transplant oncology BD teams

Business development professionals at hematology and oncology companies need daily visibility into the cGVHD competitive landscape. Incyte's aggressive axatilimab line expansion strategy — moving from 3L+ approval to first-line clinical development in under two years — is the defining competitive event in cGVHD right now. Teams tracking partnership opportunities, biosimilar development timelines, or combination drug strategies need to monitor protocol amendments, enrollment signals, and new study registrations as they happen, not 60 days later in a conference summary.

Transplant hematology analysts and investors

The cGVHD market has undergone a major structure shift since 2017. Before ibrutinib's approval, it was a treatment-free disease managed with steroids. Now there are four FDA-approved drugs with distinct mechanisms and overlapping indications, and a Phase 3 first-line trial underway. Axatilimab's first-line Phase 3 readout will be the most consequential cGVHD event since ruxolitinib's 2021 approval. Daily monitoring of NCT06585774 enrollment progress, protocol amendments, and competitive study registrations provides leading indicators before formal company announcements.

Transplant center clinical teams

Transplant physicians and APPs at high-volume allo-HSCT centers need awareness of open clinical trials for patient referral and enrollment. With multiple trials open simultaneously — Phase 3, Phase 2, and prevention studies — staying current on eligibility criteria, enrollment status, and site participation requires systematic monitoring that manual ClinicalTrials.gov searches cannot efficiently provide.

Frequently asked questions